Gleb Kuznetsov, PhD, is the Co-Founder and CEO of Manifold Bio, a platform biotechnology company pioneering AI-guided protein design and mega-scale in vivo screening to unlock tissue-targeted medicines. He founded Manifold Bio after completing his PhD in the Harvard Biophysics program in the lab of George Church, where he developed new approaches for protein measurement and design by combining high-throughput biology, DNA sequencing, DNA synthesis, and machine learning technologies. At Manifold, Gleb focuses on shaping strategy, building world-class teams, leading business development, and driving the company’s vision forward.